Aldosterone Stimulates Its Biosynthesis Via a Novel GPER-Mediated Mechanism.
Adrenal Cortex Neoplasms
/ drug therapy
Adrenocortical Adenoma
/ drug therapy
Aldosterone
/ biosynthesis
Benzodioxoles
/ pharmacology
Calcium
/ metabolism
Canrenone
/ pharmacology
Cytochrome P-450 CYP11B2
/ genetics
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Mineralocorticoid Receptor Antagonists
/ pharmacology
Quinolines
/ pharmacology
Receptor, Angiotensin, Type 1
/ genetics
Receptors, Estrogen
/ antagonists & inhibitors
Receptors, G-Protein-Coupled
/ antagonists & inhibitors
Renin-Angiotensin System
/ drug effects
Tumor Cells, Cultured
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
15
01
2019
accepted:
20
05
2019
pubmed:
28
5
2019
medline:
5
6
2020
entrez:
25
5
2019
Statut:
ppublish
Résumé
The G protein-coupled estrogen receptor (GPER) mediates an aldosterone secretagogue effect of 17β-estradiol in human HAC15 adrenocortical cells after estrogen receptor β blockade. Because GPER mediates mineralocorticoid receptor-independent aldosterone effects in other cell types, we hypothesized that aldosterone could modulate its own synthesis via GPER activation. HAC15 cells were exposed to aldosterone in the presence or absence of canrenone, a mineralocorticoid receptor antagonist, and/or of the selective GPER antagonist G36. Aldosterone synthase (CYP11B2) mRNA and protein levels changes were the study end points. Similar experiments were repeated in strips obtained ex vivo from aldosterone-producing adenoma (APA) and in GPER-silenced HAC15 cells. Aldosterone markedly increased CYP11B2 mRNA and protein expression (vs untreated samples, P < 0.001) in both models by acting via GPER, because these effects were abolished by G36 (P < 0.01) and not by canrenone. GPER-silencing (P < 0.01) abolished the aldosterone-induced increase of CYP11B2, thus proving that aldosterone acts via GPER to augment the step-limiting mitochondrial enzyme (CYP11B2) of its synthesis. Angiotensin II potentiated the GPER-mediated effect of aldosterone on CYP11B2. Coimmunoprecipitation studies provided evidence for GPER-angiotensin type-1 receptor heterodimerization. We propose that this autocrine-paracrine mechanism could enhance aldosterone biosynthesis under conditions of immediate physiological need in which the renin-angiotensin-aldosterone system is stimulated as, for example, hypovolemia. Moreover, as APA overexpresses GPER this mechanism could contribute to the aldosterone excess that occurs in primary aldosteronism in a seemingly autonomous fashion from angiotensin II.
Identifiants
pubmed: 31125081
pii: 5497102
doi: 10.1210/jc.2019-00043
doi:
Substances chimiques
Benzodioxoles
0
G36 compound
0
GPER1 protein, human
0
Mineralocorticoid Receptor Antagonists
0
Quinolines
0
Receptor, Angiotensin, Type 1
0
Receptors, Estrogen
0
Receptors, G-Protein-Coupled
0
Aldosterone
4964P6T9RB
Canrenone
78O20X9J0U
Cytochrome P-450 CYP11B2
EC 1.14.15.4
Calcium
SY7Q814VUP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6316-6324Informations de copyright
Copyright © 2019 Endocrine Society.